Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

Highlights:

  • Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation
  • Strengthening profile at investment, scientific and clinical conferences
  • Dr David Stamler appointed Chief Executive Officer
  • Cash balance as at 31 March 2021 of A$32.8M

MELBOURNE, Australia, April 29, 2021 /PRNewswire/ -- Alterity Therapeutics...

Read more: Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

More Articles …

  1. Vectra AI Raises $130 Million led by Blackstone Growth (BXG)
  2. 2021, a turning point for PQE Group: no more internal hierarchy and a hiring plan of 550 new employees
  3. Virgin Money partners with Fintech Trade Ledger as part of a new business banking proposition
  4. Asia's 50 Best Bars Reveals, For The First-time Ever, Bars Ranked Between 51st And 100th In The List
  5. New Research Indicates Pandemic as Tipping Point for Investment in ESG and Sustainability
  6. Regulators Challenged by COVID-19 Pandemic but Not Letting Businesses Off the Hook, Nuix Survey Finds
  7. Inaugural Asia Tech x Singapore Event Convenes Leaders across Governments and Businesses to Redefine the Future of Technology
  8. INEX Innovate commended by global business consulting firm Frost & Sullivan with their Singapore Women's Health Entrepreneurial Company of the Year Award.
  9. Nayax announces the launch of its initial public offering
  10. Nintex Helps Organisations Accelerate Digital Business Transformation with Pre-Built Configurable Process Maps and Automation Templates